JAK1 and graft versus host disease: Clinical trials verified that the JAK1/2 inhibitor Jakafi® (Ruxolitinib) reduces efficiently steroid-refractory GvHD (78, 79) and has recently been approved by the U.S. Food and Drug Administration (FDA).